Among patients who were anemic at ART initiation, only MCV in the lower quartile (<76.0 fL) significantly predicted persistent anemia 12 months later in bivariable logistic regression analysis adjusted for baseline hemoglobin, whereas MCH in the lower quartile (<23.8 pg) and a zidovudine-containing initial regimen were borderline significant (Table 2). This evidence concerns the gene PMCH and anemia (phenotype).